1. Opening Hook
After a quarter where pharma stocks either printed cash or excuses, Kopran decided to do both — and threw in a turnaround for drama. Q2 looked like a balance-sheet horror movie, Q3 suddenly remembered how profits work. EBITDA woke up, forex stopped bullying, and management looked visibly relieved.
But before you assume a structural comeback, remember: pharma turnarounds are famous for ghosting investors right after the first good quarter. This one has API traction, formulation momentum, and export tailwinds — but also cost pressure and volatile margins doing bhangra.
Read on, because the real story isn’t the revenue jump — it’s where the money came from and how fragile it still looks underneath.
Things get interesting. Slightly uncomfortable. Potentially rewarding.
2. At a Glance
- Revenue up to ₹19,428 lakh: From Q2’s snooze-fest to Q3’s caffeine shot.
- EBITDA jumps to ₹2,023 lakh: From ₹296 lakh — no, that’s not a typo.
- EBITDA margin at 10.4%: Still below last year, but breathing again.
- Net profit ₹934 lakh: After a ₹992 lakh loss in Q2, finance team finally smiled.
- Forex loss shrank: Currency markets stopped treating Kopran like a punching bag.
3. Management’s Key Commentary
“Q3 reflects normalization of operations across both API and formulation segments.”
(Translation: Q2 was a mess, let’s never talk about it again. 😏)
